Growth inhibitory effects of flavonoids in human thyroid cancer cell lines

Thyroid

Volumn 9, Issue 4, 1999, Pages 369-376

  Yin, Fen ^a   Giuliano, Armando E ^b   Van Herle, Andre J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; APIGENIN; BIOCHANIN A; CHRYSIN; ESTRADIOL; ESTROGEN RECEPTOR; FLAVONOID; GENISTEIN; KAEMPFEROL; LUTEOLIN; TAMOXIFEN; TRITIUM;

ANAPLASTIC CARCINOMA; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

EID: 0033004673     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.1999.9.369     Document Type: Article

References (45)

1. Coward L, Barnes S, Setchell KDR, Barnes S 1993 Genistein and daidzein, and their β-glycoside conjugates: Anti-tumor isoflavones in soybean foods from American and Asian diets. J Agric Food Chem 41:1961-1967.
2. Ito A, Watanabe H, Basaran N 1993 Effects of soy products in reducing risk of spontaneous and neutron-induced liver tumors in mice. Int J Oncol 2:773-776.
3. Messina MJ, Barnes S 1994 The role of soy products in reducing risk of cancer. J Natl Cancer Inst 83:541-546.
4. Messina MJ, Persky V, Setchell KDR, Barnes S 1994 Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer 21:113-131.
5. Hirayama T 1977 Epidemiological correlations between diet and cancer frequency. In: Hiatt HH, Watson JD, Winsten JA, (eds) Origins of Human Cancer. Book A. Incidence of Cancer in Humans Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp 55-75.
6. Saio K 1984 Dietary pattern and soybean procession in Japan today. Trop Agric Res Serv 17:153-161.
7. Lamartiniere CA, Moore J, Holland M, Barnes S 1995 Neonatal genistein chemoprevents mammary cancer. Proc Soc Exp Biol Med 208:120-123.
8. Peterson G, Barnes S 1991 Genistein inhibition of the growth of human breast cancer cells: Independence from estrogen receptors and the multi-drug resistance gene. Biochem Biophys Res Commun 179:661-667.
9. Peterson G, Barnes S 1996 Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. Cell Growth Diff 7:1345-1351.
10. So FV, Guthrie N, Chambers AF, Carroll KK 1997 Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by flavonoids in the presence and absence of excess estrogen. Cancer Lett 112:127-133.
11. Peterson G, Barnes S 1993 Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate 22:335-345.
12. Santibanez JF, Navarro A, Martinez J 1997 Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Anticancer Res 17:1199-1204.
13. Samaan NA, Maheshwari YK, Nader S, Hill CS Jr 1983 Impact of therapy for differentiated carcinoma of the thyroid: An analysis of 706 cases. J Clin Endocrinol Metab 56:1131-1138.
14. Lindsay RH, Gaitan E, Cooksey RC 1989 Pharmacokinetics and intrathyroidal effects of flavonoids. In: Gaitan E, ed. Environmental Goitrogenesis. CRC Press, Boca Raton, FL, pp 43-56.
15. Cody V, Koehrle J, Hesch RD 1989 Structure-activity relationships of flavonoids as inhibitors of iodothyronine deiodinase. In Gaitan E, (ed) Environmental Goitrogenesis. CRC Press, Boca Raton, FL, pp 57-69.
16. Barnes S, Peterson G, Grubbs C, Setchell K 1994 Potential role of dietary isoflavones in the prevention of cancer. In: Jacobs MM (ed). Diet and Cancer: Markers, Prevention, and Treatment. New York, Plenum Press, pp 135-147.
17. 2 regulated cell proliferation in four human thyroid cancer cell lines. Thyroid Clin Exp 8:79-86.
18. Gross C, Yu M, Van Herle AJ, Giuliano AE, Juillard GJF 1993 Presence of a specific antiestrogen binding site on human follicular thyroid carcinoma cell line (UCLA RO 82 W-I): Inhibition by an endogenous ligand present in human serum. J Clin Endocrinol Metab 77:1361-1366.
19. Folman Y, Pope GS 1966 The interaction in the immature mouse of potent oestrogens with coumestrol, genistein and other utero-vaginotrophic compounds of low potency. J Endocrinol 34:215-225.
20. Collins BM, McLachlan JA, Arnold SF 1997 The estrogenic and antiestrogenic activities of phytochemicals with the human estrogen receptor expressed in yeast. Steroids 62:365-372.
21. Kuriu A, Ikeda H, Kanakura Y, Griffen JD, Druker B, Yagura H, Kitayama H, Ishikawa J, Nishiura T, Kanayama Y, Yonezawa T, Tarui S 1991 Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the pro-oncogene c-kit product. Blood 78:2834-2840.
22. Cunningham BDM, Threadgill MD, Groundwater PW, Dale II, Hickman JA 1992 Synthesis and biological evaluation of a series of flavones designed as inhibitors of protein tyrosine kinases. Anticancer Drug 7:365-384.
23. Okura A, Arakawa H, Oka H, Yoshinai T, Monden Y 1988 Effect of genistein on topoisomerase activity and on the growth of [val 12] Ha-Ras-transformed NIH 3T3 cells. Biochem Biophys Res Commun 157:183-189.
24. Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier J-M, Le Pecq J-B, Larsen AK 1989 Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Res 49:5111-5117.
25. Linassier C, Pierre M, Le Peco J-B, Pierre J 1990 Mechanism of action in NIH-3T3 cells of genistein, an inhibitor of EGF-receptor tyrosine kinase activity. Biochem Pharmacol 39:187-193.
26. Makishima M, Honma Y, Hozumi M, Sampi K, Hattori M, Umezawa K, Motoyoshi K 1991 Effects of inhibitors of protein thyrosine kinase activity and/or phosphoatidylinositol turnover on differentiation of some human myelomonocytic leukemia cells. Leukemia Res 15:701-708.
27. Markaverich BM, Roberts RR, Alejandro MA, Johnnan GA, Middleditch BS, Clark JH 1988 Bioflavonoid interaction with rat uterine type II binding site and growth inhibition. J Steroid Biochem 30:71-78.
28. Scambia G, Ranelletti FO, Benedetti Panici P, Piantelli M, Bonanno G, De Vincenzo R, Ferrandina G, Rumi C, Larocca LM, Mancuso S 1990 Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumors and cultured cells. Br J Cancer 62:942-946.
29. Ranelletti FO, Ricci R, Larocca LM, Maggiano N, Capelli A, Scambia G, Mancuso S, Rumi C, Piantelli M 1992 Growth-inhibitory effect of quercetin and presence of type II estrogen-binding sites in human colon-cancer cell lines and primary tumors. Int J Cancer 50:486-492.
30. Larocca LM, Teofili L, Leone G, Sica S, Menichella G, Scambia G, Benedetti Panici P, Ricci R, Piantelli M, Ranelletti FO 1991 Antiproliferative activity of quercetin on normal bone marrow and leukaemic progenitors. Br J Haematol 79:562-566.
31. Piantelli M, Maggiano N, Ricci R, Larocca LM, Capelli A, Scambia G, Isola G, Natali PG, Ranelletti FO 1995 Tamoxifen and quercetin interact with type II estrogen binding sites and inhibit the growth of human melanoma cells. J Invest Dermatol 105:248-253.
32. Markaverich BM, Alejandro MA 1998 Type II [3H] estradiol binding site antagonists: Inhibition of normal and malignant prostate cell growth and proliferation. Int J Oncol 12:1127-1135.
33. Ho SM, Leav I, Merk FB, Yu M, Kwan PW Ziar J 1995 Induction of atypical hyperplasia, apoptosis, and type II estrogen-binding sites in the ventral prostates of Noble rats treated with testosterone and pharmacologic doses of estradiol-17 beta. Lab Invest 73:356-365.
34. Caltagirone S, Ranelletti FO, Rinelli A, Maggiano N, Colasante A, Musiani P, Aiello FB, Piantelli M 1997 Interaction with type II estrogen binding sites and antiproliferative activity of tamoxifen and quercetin in human non-small-cell lung cancer. Am J Respir Cell Mol Biol 17:51-59.
35. Marsigliante S, Biscozzo L, Barker S, Leo G, Puddefoot JR, Vinson GP 1992 Type II oestrogen binding site is associated with the major 4S oestrogen receptor isoform in breast tumors. J Steroid Biochem Molec Biol 42:777-781.
36. Wang TTY, Sathyamoorthy N, Phang JM 1996 Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis 17:271-275.
37. Viola H, Wasowski C, Levi de Stein M, Wolfman C, Silveira R, Dajas F, Medina JH, Paladini AC 1995 Apigenin, a component of Matricaria recutita flowers, is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med 61:213-216.
38. Medina JH, Viola H, Wolfman C, Marder M, Wasowski C, Calvo D, Paladini AC 1997 Overview-Flavonoids: A new family of benzodiazepine receptor ligand. Neurochem Res 22:419-425.
39. Jing YK, Waxman S 1995 Structure requirements for differentiation-induction and growth-inhibition of mouse erythroleukemia cells by isoflavones. Anticancer Res 15:1147-1152.
40. Fotsis T, Pepper MS, Aktas E, Breit S, Rasku S, Adlercreutz H, Wahala K, Montesano R, Schweigerer L 1997 Flavonoids, dietary-derived inhibititors of cell proliferation and in vitro angiogenesis. Cancer Res 57:2916-2921.
41. Birt DF, Mitchell D, Gold B, Pour P, Pinch H 1997 Inhibition of ultraviolet light induced skin carcinogenesis in SKH-1 mice by apigenin, a plant flavonoid. Anticancer Res 17:85-92.
42. Ferriola PC, Cody V, Middleton EJ 1989 Protein kinase C inhibition by plant flavonoids. Biochem Pharmacol 38:1617-1624.
43. Agullo G, Payrastre LG, Manenti M, Viala C, Remesy C, Chap H, Payrastre, B 1997 Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: A comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53:1649-1657.
44. Kuo ML, Yang NC 1995 Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes. Biochem Biophys Res Commun 212:767-775.
45. 1 cell-cycle arrest by the chemopreventive agent apigenin. Mol Carcinogenesis 19:74-82.